P2176
P3781
A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delNovel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon MutationsStudy of VX-121 in Healthy Subjects and in Subjects With Cystic FibrosisA Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult SubjectsA Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR MutationReal-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-IvacaftorA Study of VX-445 in Healthy Subjects and Subjects With Cystic FibrosisA Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR MutationCystic Fibrosis Related Bone Disease: the Role of CFTRStudy of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) MutationSafety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508delLum-Iva-biota: Exploring the Respiratory Mycobiota and Microbiota Profile in French CF Patients Taking Lumacaftor-IvacaftorIvacaftor for Acquired CFTR Dysfunction in Chronic RhinosinusitisA Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination TherapyA Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF): TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)Canadian Observation Trial in CF Patients Undergoing Treatment With IvacaftorA Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyA Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisIvacaftor Treatment in 1 to 2 Year Old CF SubjectsPersonalized Theratyping TrialA Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (2013-05-31)A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesA Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
P4844
A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung diseaseCystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutationIvacaftor, vismodegib, and ingenol mebutate.Ivacaftor potentiation of multiple CFTR channels with gating mutations.Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T - a case reportThe combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapyEmerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized MedicineLumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azolesIvacaftor (Kalydeco) for cystic fibrosisACP Journal Club. Ivacaftor improved lung function in cystic fibrosis with G551D mutationIvacaftorPersonalized medicine in cystic fibrosis: dawning of a new era
P921
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Ivacaftor
@es
Ivacaftor
@nl
Ivakaftor
@sh
Ivakaftor
@sl
Ivakaftor
@sr
ivacaftor
@en
ivacaftor
@fr
iwakaftor
@pl
איבקפטור
@he
ایواکافتور
@azb
type
label
Ivacaftor
@es
Ivacaftor
@nl
Ivakaftor
@sh
Ivakaftor
@sl
Ivakaftor
@sr
ivacaftor
@en
ivacaftor
@fr
iwakaftor
@pl
איבקפטור
@he
ایواکافتور
@azb
altLabel
Ivacaftor
@en
Ivacaftor
@sr
Ivacaftorum
@en
Kalideko
@sr
Kalydeco
@sr
N-(2,4-di-tert-butil-5-hidroksifenil)-4-okso-1,4-dihidrohinolin-3-karboksamid
@sr
N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
@en
VX-770
@en
VX-770
@pl
VX-770
@sr
prefLabel
Ivacaftor
@es
Ivacaftor
@nl
Ivakaftor
@sh
Ivakaftor
@sl
Ivakaftor
@sr
ivacaftor
@en
ivacaftor
@fr
iwakaftor
@pl
איבקפטור
@he
ایواکافتور
@azb